Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples